Xenon (Xe) - Comprehensive Pharmacology

1. Group / Classification

• Chemical Group: Noble gas (Group 18 / Group VIII A of the Periodic Table)
• Class: Inhalational anaesthetic agent; monoatomic inert gas
• Atomic Number: 54
• Molecular Weight: 131 g/mol
• Xenon is the only elemental anaesthetic - it is a single atom, not a compound

2. Chemical Structure

• Formula: Xe (monoatomic)
• Xenon is a noble gas with a completely filled outer electron shell (8 valence electrons in 5p orbital)
• It has no chemical bonds, no reactive electrons, no appendages to engage biological entities
• It is colorless, odorless, tasteless
• Because it is monoatomic with no dipole moment, its anaesthetic action is purely through physical occupation of protein hydrophobic cavities (consistent with Meyer-Overton correlation)
• Boiling point: -108°C
• Density: 5.9 g/L (much heavier than air at 1.2 g/L or N₂O at 1.9 g/L)

3. Formulation

• Xenon is not chemically synthesized - it is extracted by fractional distillation of liquefied air (cryogenic separation)
• It exists naturally in the atmosphere at ~90 parts per billion
• Supplied as a pure compressed gas (medical-grade Xe ≥99.999% purity)
• No additives or preservatives required - unlimited shelf life
• Used as a gas mixture with oxygen (typically 60-65% Xe + 30-35% O₂) for anaesthesia
• The gas does not react with CO₂ absorbents (soda lime), ultraviolet light, or anaesthetic machine components
• Not flammable or explosive

4. Dilution

• Xenon is administered as a binary mixture with oxygen - no other carrier gas needed
• Standard anaesthetic mixture: 60-70% Xe + 30-40% O₂
• Unlike N₂O, nitrogen (room air) must be purged first (denitrogenation phase) before starting xenon delivery, as nitrogen accumulates in the closed circuit
• Flow rates vary by delivery technique:
  • Closed-circuit technique: Low-flow delivery after denitrogenation; xenon is added slowly to replace metabolized O₂
  • High-flow induction: Rapid induction at high flows (more xenon waste/expense)
• Xenon is not diluted in liquids or solvents - purely gaseous administration

5. Available Forms in Market

• Marketed as: LENOXe® (Air Liquide, Europe - approved in the EU in 2007 under EMA), XenonMedical®, various national medical gas suppliers
• Forms:
  • High-pressure medical-grade gas cylinders (compressed gas)
  • Pre-mixed cylinders (Xe + O₂) available in some markets
• Regulatory status:
  • Approved: European Union (EMA, 2007), Russia, some Eastern European countries
  • NOT approved: USA (no FDA approval as of 2026); used only under research/investigational protocols
• Cost: >$10/L of gas - extremely expensive compared to other inhalational agents; closed-circuit delivery systems and cryogenic scavenging traps exist to recapture and repurify xenon for reuse

6. Routes of Administration

• Exclusively via inhalation - delivered as an inspired gas mixture through an anaesthetic circuit
• Requires a closed-circuit anaesthetic machine or specially designed rebreathing circuit for cost-effective delivery
• Administered via endotracheal tube, laryngeal mask airway (LMA), or tight-fitting face mask
• Specialized systems include:
  • Cryogenic scavenging traps to recapture waste gas
  • Low dead-space circuits to minimize xenon loss
• Cannot be given intravenously, orally, or by any other route

7. Dosage

• Dosage is titrated to clinical effect (loss of consciousness, hemodynamic response) rather than strict mg/kg dosing
• Combined with opioids/adjuvants, the required xenon concentration is reduced (opioid-sparing effect)

8. Mechanism of Action

Primary Mechanism

• Non-competitive antagonism of NMDA receptors (N-methyl-D-aspartate receptors)
  • Xenon inhibits NMDA receptors at the glycine co-agonist site (competitive inhibition at glycine site; also described as non-competitive overall)
  • Blocks ion channel opening → inhibits glutamatergic excitatory neurotransmission
  • This is also the primary mechanism of its neuroprotective properties (limiting excitotoxicity)

Secondary / Additional Mechanisms

• Activation of TREK-1 (two-pore K⁺ channels / TREK two-pore domain potassium channels): Hyperpolarization of neurons → reduced excitability
• Inhibition of AMPA and kainate receptors: Further reduces glutamate-mediated excitation
• Inhibition of nACh receptors (nicotinic acetylcholine receptors): Contributes to immobility
• HCN1 channel inhibition (hyperpolarization-activated cyclic nucleotide-gated channels)
• Physical mechanism (Meyer-Overton): The smooth, spherical xenon atom occupies hydrophobic protein cavities - essentially a "billiard ball" rolling into ion channel pockets and disrupting conformational changes
• Xenon does NOT act on GABA-A receptors (unlike propofol, benzodiazepines, and halogenated agents) - this accounts for its unique hemodynamic stability

Analgesic mechanism

• NMDA antagonism provides analgesic activity similar to N₂O - reduces intraoperative opioid requirements

9. Pharmacokinetics

10. Pharmacodynamics

CNS

• Produces dose-dependent hypnosis, amnesia, and analgesia
• Reduces CBF by ~15% in cortex, ~35% in cerebellum; white matter CBF increases ~22% at 1 MAC
• Reduces cerebral metabolic rate of glucose (CMRg) by ~26%
• Cerebral autoregulation and CO₂ reactivity are preserved (unlike volatile halogenated agents)
• Does not increase ICP - favorable for neuroanesthesia
• Does not trigger epileptiform activity

Cardiovascular

• Produces minimal cardiovascular depression - most hemodynamically stable inhalational agent
• Does not reduce myocardial contractility significantly (no Ca²⁺ channel blockade, no NO-mediated vasodilation unlike volatile agents)
• Maintains stable blood pressure and tends to produce a modest reduction in heart rate
• Not arrhythmogenic
• Cardioprotective - preclinical and clinical evidence shows reduced pressor requirements in cardiac surgery; reduces infarct size in ischemia-reperfusion models
• Useful in high-risk cardiac surgery patients

Respiratory

• Causes mild respiratory depression (↓ tidal volume, ↑ RR)
• High density (5.9 g/L) → increased airway resistance and work of breathing compared to other agents - significant in patients with obstructive lung disease
• Increase in airway resistance with 70% Xe + 30% O₂ vs. 70% N₂ + 30% O₂ is clinically modest in healthy patients

Other

• Does not trigger malignant hyperthermia
• No organ toxicity - no hepatotoxicity, nephrotoxicity, or neurotoxicity
• Neuroprotective - in preclinical ischemia/TBI models; clinical evidence in cardiac surgery and cardiac arrest survivors shows reduced organ damage but no improvement in survival/neurocognitive outcomes
• Opioid-sparing effect through NMDA antagonism
• Environmentally neutral - does not contribute to greenhouse gas emissions or ozone depletion

11. Indications

1. General anaesthesia (induction and maintenance) for elective surgery - particularly where cardiovascular stability is paramount (cardiac surgery, high-risk patients)
2. Cardiac surgery - reduced pressor requirements, cardioprotection
3. Outpatient/day surgery - rapid, clear-headed recovery with minimal PONV (compared to volatile agents, though PONV is higher vs. propofol/TIVA)
4. Neuroanesthesia - favorable CNS profile (preserved autoregulation, no ICP rise)

12. Contraindications

1. Closed gas space conditions: Pneumothorax, bowel obstruction, intracranial air (pneumocephalus), middle ear/sinus surgery where trapped gas expansion is dangerous (less risk than N₂O but still present)
2. Severe obstructive lung disease (COPD, severe asthma) - increased airway resistance and work of breathing due to high gas density
3. Situations requiring high FiO₂ - xenon must occupy ≥60% of inspired mixture, limiting maximum FiO₂ to ~40%

13. Adverse Effects

14. Special Points

1. Cost and availability are the primary barriers to clinical adoption - >$10/L; requires closed-circuit delivery and cryogenic scavenging for economical use
2. No FDA approval - approved in EU (LENOXe®, 2007), Russia, and several other countries; NOT yet approved in the USA
3. Ideal anaesthetic profile - Xenon is the closest agent to the theoretical "ideal anaesthetic": no metabolism, no organ toxicity, hemodynamic stability, rapid onset/offset, analgesic activity, neuroprotection, environmentally neutral
4. Denitrogenation required - Before xenon anaesthesia, nitrogen washout (breathing 100% O₂ for several minutes) is mandatory to prevent N₂ accumulation in the rebreathing circuit
5. Hyperpolarized ¹²⁹Xe MRI - Xenon-129, when hyperpolarized, is an outstanding MRI contrast agent for lung ventilation imaging and pulmonary function assessment in 3D
6. Xenon-133 (¹³³Xe) - radioactive isotope used in nuclear medicine for ventilation-perfusion (V/Q) lung scans and cerebral blood flow measurement
7. Cardioprotection mechanism - Xenon activates survival kinase pathways (PI3K/Akt, ERK1/2), mimics ischemic preconditioning, reduces apoptosis in ischemic myocardium - demonstrated in MYRIAD trial and other cardiac surgery RCTs
8. Neuroprotection mechanism - NMDA antagonism reduces excitotoxic calcium influx; activates HIF-1α and other survival pathways; synergistic with hypothermia in animal TBI/HIE models
9. Does not accumulate in obese patients unlike many lipid-soluble volatile agents - very low oil:gas coefficient (1.9)
10. Higher PONV compared to propofol-TIVA - antiemetic prophylaxis should be considered
11. Emerging use in addiction medicine - 2025 research suggests xenon (via NMDA antagonism) may attenuate opioid and alcohol craving/withdrawal

Quick Reference Summary Table

• Miller's Anesthesia, 10th Edition (Elsevier), Chapters 10 & 62 - the primary reference for all clinical data above
• McGuigan et al. (2023). Cellular mechanisms of xenon: systematic review. Frontiers in Neuroscience. PMID 37521706
• Yang et al. (2023). Xenon and postoperative neurocognitive disorders: meta-analysis. BMC Anesthesiology. PMID 37946114
• Shi et al. (2025). Xenon and the developing brain. Journal of Integrative Neuroscience. PMID 40152563
• LITFL Inhalational Anaesthetic Agents